

Natraj Proteins Limited
SOLVENT EXTRACTION PLANT & REFINERY
Nagpur Kalan, Ordinance Factory Road, ITARSI
Ph.No. 07572- 262637, 262640, Fax No. 07572-262639
Email : natrajproteinltd@rediffmail.com
CIN : L00153 MP 1990 PLC 006090



Ref. :

Date :

NPL/SE/2023

15th Feb., 2023

online filing at www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
MUMBAI - 400001

BSE CODE: 530119

Subject: Submission of Reply to the E-mail dated 14th February, 2023 regarding discrepancies observed by the BSE for Corporate Announcement filed u/r 30 of SEBI (LODR) Regulations, 2015 for Submission of the Standalone Un-Audited Financial Results & Limited Review Report for the Quarter/Nine Months ended 31st December, 2022 u/r 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir/Ma'am,

This is with reference to the above captioned subject, regarding Additional details required by the email dated 14th February, 2023 at 3:43 P.M. as required under SEBI Circular dated September 09, 2015, for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015 with respect to the Submission of the Standalone Un-Audited Financial Results & Limited Review Report for the Quarter/Nine Months ended 31st December, 2022 u/r 33 of the SEBI (LODR) Regulations, 2015 observed by the BSE that **"Board Meeting Concluded Time not Given"**.

It may please be considered that the **said Board Meeting was concluded at 4:45 P.M. on 13th February, 2023** and the time of meeting conclusion was also disclosed while filing of results in the XBRL at the portal of BSE. This may be considered as compliance as required under Regulation 30 of the SEBI (LODR) Regulation as required under in the Para No. 4 of the Annexure of the Circular No. CIR/CFD/CMD/4/2015 dated 09.09.2015.

As per the aforesaid email we are pleased to submit a fresh corporate announcement for the aforesaid purposes.

I humbly request you to take the above clarification and take on record the aforesaid fresh corporate announcement on record.

Thanking You,
Yours Faithfully,

For, NATRAJ PROTEINS LIMITED

Pooja
Agrawal

Digitally signed by Pooja
Agrawal
Date: 2023.02.15 13:34:54
+05'30'



POOJA AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER

Encl: Fresh Corporate Announcement Letter

Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090



Ref. :

Date :

NPL/SE/2023

15th Feb., 2023

online filing at www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
MUMBAI - 400001

BSE CODE: 530119

Sub: Submission of the Standalone Un-Audited Financial Results & Limited Review Report for the Quarter/Nine Months ended 31st December, 2022 u/r 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir,

This is in continuation of our letter no. NPL/SE/2023 dated 25th January, 2023 regarding intimation of Board meeting for consideration and approval of the Quarterly/Nine Monthly Standalone Un-Audited Financial Results & Limited Review Report thereon, for the Quarter/Nine Months ended 31st December, 2022.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015 we are pleased to submit the following;
(c) Standalone Unaudited Financial Results for the Quarter/Nine Months ended 31st December, 2022; and
(d) Limited Review Report by the Auditors for the quarter ended 31st December, 2022,

Which was considered and approved by the Board at their 05/2022-23 Meeting held on Monday, the 13th February, 2023 at 3:00 P.M. and **Concluded at 4:45 P.M.**

The Financial Results will also be published in widely circulated English and Hindi (Vernacular) newspaper in the prescribed format for that purpose.

We are also in process of filing the aforesaid financial results in the XBRL format within the stipulated time and same shall be hosted on the Website of the Company.

You are requested to please take on record the above said Standalone Unaudited financial results & Limited Review Report for your reference and record.

Thanking You,
Yours Faithfully,
For, NATRAJ PROTEINS LIMITED

Kailash Chand Sharma
Digitally signed by Kailash Chand Sharma
Date: 2023.02.15 14:36:28 +05'30'

KAILASH CHAND SHARMA
CHAIRMAN & MANAGING DIRECTOR
DIN: 00012900



Encl.: Standalone Unaudited Financial Results and Limited Review Report

NATRAJ PROTEINS LIMITED

CIN: L00153MP1990PLC006090

Regd. Off. -Nagpur Kalan, Ordinance Factory Road, Itarsi, (M.P.)-461111

Email: natrajproteinltd@rediffmail.com Website: www.natrajproteins.com

Statement of Standalone Unaudited Financial Statements for the Quarter/Nine Months Ended on 31st December, 2022

(Rupees in Lakhs except EPS)

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31/12/2022	30/09/2022	31/12/2021	31/12/2022	31/12/2021	31/03/2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	4093.34	3030.51	4904.01	9357.00	11230.26	14471.18
II	Other Income	3.39	2.41	3.76	7.73	19.48	26.40
III	Total Income (I+II)	4096.73	3032.92	4907.77	9364.73	11249.74	14497.58
IV	EXPENSES						
a	Cost of materials consumed	4417.34	892.65	5311.82	6190.47	7716.76	10448.52
b	Purchases of Stock-in-Trade	218.45	446.60	527.43	2181.21	811.75	1651.89
c	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(926.90)	1644.02	(1191.62)	375.39	381.59	220.08
d	Employee benefits expense	29.51	24.12	32.63	85.38	90.02	139.37
e	Finance costs	37.21	22.79	12.79	110.47	55.07	107.25
f	Depreciation and amortization expense	11.05	10.44	9.88	31.81	29.64	39.60
g	Other expenses	207.15	48.48	164.57	328.87	368.08	595.25
	Total expenses (IV)	3993.81	3089.10	4867.50	9303.60	9452.91	13201.96
V	Profit/(loss) before exceptional items, extraordinary items and tax (III- IV)	102.92	(56.18)	40.27	61.13	1796.83	1295.62
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) before extraordinary items and tax (V-VI)	102.92	(56.18)	40.27	61.13	1796.83	1295.62
VIII	Extraordinary Items	-	-	-	-	-	-
IX	Profit/(loss) before tax (VII-VIII)	102.92	(56.18)	40.27	61.13	1796.83	1295.62
X	Tax expense:						
	(1) Current tax	7.42	(1.32)	7.18	7.42	429.10	341.68
	(2) Deferred tax	3.17	2.76	1.31	9.47	(2.16)	(13.18)
	(3) Income tax related to earlier years	-	-	-	-	-	4.54
XI	Profit (Loss) for the period from continuing operations (IX-X)	92.33	(57.62)	31.78	44.24	1369.89	936.22
XII	Profit/(loss) from discontinued operations (before tax)	-	-	-	-	-	-
XIII	Tax expense of discontinued operations	-	-	-	-	-	-
XIV	Profit/(loss) from Discontinued operations (after tax) (XII-XIII)	-	-	-	-	-	-
XV	Net Profit/(loss) for the period (XI+XIV)	92.33	(57.62)	31.78	44.24	1369.89	936.22
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	4.62	(0.95)	(6.86)	6.50	4.78	4.29
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(1.25)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-



XVII	Total Comprehensive Income for the period (XV-XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	96.95	(58.57)	24.92	50.74	1374.67	939.26
XVIII	Paid up Equity Share Capital (Face Value Rs.10 per share)	374.70	374.70	374.70	374.70	374.70	374.70
XIX	Reserves (excluding Revenue Reserve) as shown in the audited balance sheet of the previous year.	-	-	-	-	-	4171.25
XX	Earnings per equity share (for continuing operations)						
	(1) Basic	2.46	(1.53)	(0.85)	1.18	36.56	24.99
	(2) Diluted	2.46	(1.53)	(0.85)	1.18	36.56	24.99
XXI	Earnings per equity share (for Discontinued operations)						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XXII	Earnings per equity share (for continuing and Discontinued operations)						
	(1) Basic	2.46	(1.53)	(0.85)	1.18	36.56	24.99
	(2) Diluted	2.46	(1.53)	(0.85)	1.18	36.56	24.99

For, NATRAJ PROTEINS LIMITED

Date: 13.02.2023
Place: Itarsi


KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900



NATRAJ PROTEINS LIMITED

CIN- L00153MP1990PLC006090

Regd. Office: Nagpur Kalan, Ordinance Factory Road, Itarsi (M.P.) 461111

Contact No.: 07572-262637, Email ID: natrajproteinltd@rediffmail.com, Website :www.natrajproteins.com

SEGMENT WISE REVENUE, RESULTS, SEGMENT ASSETS AND SEGMENT LIABILITIES FOR THE NINE MONTHS ENDED ON 31ST DECEMBER, 2022							(Rs. in Lakhs)
Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Segment Revenue						
	(a) Segment – A: Manufacturing	3,558.83	1,775.73	4,815.07	7,528.35	10,793.71	13,637.63
	(b) Segment – B: Other Segments	533.09	1,254.78	88.94	1,827.23	436.55	833.55
	(c) Unallocated	4.81	2.41	3.76	9.15	19.48	26.40
	Total	4,096.73	3,032.92	4,907.77	9,364.73	11,249.74	14,497.58
	Less: Inter Segment Revenue	0	-	-	-	-	-
	Total Segment Revenue	4,096.73	3,032.92	4,907.77	9,364.73	11,249.74	14,497.58
2	Segment Results (Profit)(+)/ Loss (-) before tax, Depreciation and interest from Each segment)						
	(a) Segment – A: Manufacturing	183.25	(99.35)	59.18	96.19	1,862.06	2,104.62
	(b) Segment – B: Other Segments	-36.88	73.99	-	98.07	-	(688.55)
	(c) Unallocated	4.81	2.41	3.76	9.15	19.48	26.40
	Total	151.18	(22.95)	62.94	203.41	1,881.54	1,442.47
	Less: Finance Cost						
	(a) Segment – A: Manufacturing	37.21	22.79	12.79	110.47	55.07	107.25
	(b) Segment – B: Other Segments	-	-	-	-	-	-
	Less: Depreciation						
	(a) Segment – A: Manufacturing	11.05	10.44	9.88	31.81	29.64	39.60
	(b) Segment – B: Other Segments	-	-	-	-	-	-
	ii) Other Un-allocable Expenditure net off	-	-	-	-	-	-
	iii) Un-allocable income	-	-	-	-	-	-
	Profit Before Tax	102.92	(56.18)	40.27	61.13	1,796.83	1,295.62
	Less : Current Tax	7.42	(1.32)	7.18	7.42	429.10	341.68
	Less : Deferred Tax	3.17	2.76	1.31	9.47	(2.16)	(13.18)
	Less:Income tax related to earlier years	-	-	-	-	-	4.54
	Profit After Tax	92.33	(57.62)	31.78	44.24	1,369.89	962.58
3	Segment Assets						
	(a) Segment – A: Manufacturing	7,484.03	5,727.43	8,692.40	7,484.03	8,692.40	7,111.95
	(b) Segment – B: Other Segments	207.58	600.31	98.47	207.58	98.47	129.79
	(c) Unallocated	669.51	467.73	534.42	669.51	534.42	336.95
	Total						
4	Segment Liabilities						
	(a) Segment – A: Manufacturing	3,763.43	2,295.73	4,347.72	3,763.43	4,347.72	3,032.49
	(b) Segment – B: Other Segments	1.00	-	-	1.00	-	0.25
	(c) Unallocated	-	-	-	-	-	-
	Total	4,596.69	4,499.74	4,977.57	4,596.69	4,977.57	4,545.95
	Net Capital Employed	4,596.69	4,499.74	4,977.57	4,596.69	4,977.57	4,545.95

Notes :-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 13th February, 2023.
- The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] as amended.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- As required under Regulation 33 of SEBI (LODR) Regulation, 2015 the Limited Review by the Statutory Auditors have been completed for the quarter and nine months ended on 31st December, 2022. The report does not have any impact on the above results and notes which need explanations.
- Effective from 1st April, 2019, the company has adopted Indian Accounting Standard (IND-AS 116) "Leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1st April, 2022 and there was no material impact on financial results for the quarter ended on 31st December, 2022.
- Government of India's Code for Social Security 2020 ("the Code") received assent from the President in September 2020. However, the date from when the Code will become applicable and the rules have not yet been notified. Company will assess the impact of the Code and account for the same once the effective date and the rules are notified.
- The company operates in two segments i.e. solvent extraction and commodities/derivative trading. The particulars of segment wise results are given as required. However, for the quarter ended 31.12.2021 and Nine months ended 31.12.2021, the bifurcation of profit is not given as in that period there was no requirement of segmental reporting as the sales of commodities/derivatives are less than the threshold limits.

Date: 13.02.2023
Place: Itarsi

For, NATRAJ PROTEINS LIMITED

KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900





**Limited Review Report on Un-Audited Standalone Quarterly and Nine
Monthly Financial Results of the Company**

*(Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended)*

To,
The Board of Directors of
NATRAJ PROTEINS LIMITED
Itarsi (M.P.)

We have reviewed the accompanying statement of unaudited Standalone financial results of Natraj Proteins Limited for the period ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 (the Statement) attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended.

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting standard 34 "Interim Financial Reporting" ("Ind AS-34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended ("Listing Regulation"). Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Bhutoria Ganesan & Co.,
Chartered Accountants,
FRN No. 004465C**

**Place: Bhopal
Date: 13.02.2023
UDIN: 23402792BGYXRG4702**



**CA R. Gokulkrishnan
Partner
M. No. 402792**